Press Releases

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells   University of California/University of Vienna /Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology

CAMBRIDGE, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in September: Tuesday,

  Robust, dose-responsive liver editing and reduction of TTR protein shown  in humanized mouse model Therapeutically relevant reduction of serum TTR protein correlating with liver editing achieved in non-human primates after a single dose CAMBRIDGE, Mass. , Aug.

CAMBRIDGE, Mass. , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, will host an educational briefing session for investors addressing the interference proceedings

Continued to progress lead in vivo program in transthyretin amyloidosis targeting submission of an Investigational New Drug application by the end of 2019 Announced first wholly owned ex vivo T cell receptor program targeting a unique epitope of Wilms’ Tumor 1 protein for the treatment of acute

Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR

CAMBRIDGE, Mass. , May 17, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator , Ospedale San Raffaele (OSR), presented at the 21 st Annual

CAMBRIDGE, Mass. , May 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new scientific advisors in immuno-oncology and autoimmunity.

New CEO puts in vivo and ex vivo genome editing on parallel tracks towards the clinic  Company anticipates submitting its in vivo Investigational New Drug application by the end of 2019 for systemic lipid nanoparticle delivery of CRISPR/Cas9 to potentially cure transthyretin amyloidosis

CAMBRIDGE, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced that two scientific abstracts have been accepted for presentation at the 21